Pancreatic hamartoma is a rare benign tumor that can be easily misdiagnosed due to its rarity. Its diagnostic ambiguity demands surgical resection for confirmation. We reported a 54-year-old female patient with a pancreatic hamartoma that was pathologically confirmed after surgery, and we reviewed all the reported literature for adult pancreatic hamartomas. With the advancement of techniques for minimally invasive surgery, laparoscopic or robotic pancreatectomy can be safely performed on benign or low-grade malignant tumors in which the diagnosis is uncertain. 
INTRODUCTION
A hamartoma is a benign tumor-like malformation that resembles a neoplasm in the tissue of its origin. Although the etiology is not well known, it has been demonstrated that a hamartoma is composed of normal tissue elements at the affected site, and these tissues grow in a disorganized manner. 1 Hamartomas can arise from different places in the body, and the lungs are the most common site. A pancreatic hamartoma is extremely rare and composes less than 1% of all hamartomas. 2 Its rarity makes the pancreatic hamartoma difficult to differentiate from other benign or low-grade malignant tumors, and radiologic features are not well established. Thus, the confirmative diagnosis of a pancreatic hamartoma is made by histopathological and immunohistochemical results after surgical resection. In this report, we presented a case of pancreatic hamartoma that was pathologically confirmed after minimally invasive pancreaticoduodenectomy and also reviewed the literature relevant to pancreatic hamartomas.
CASE

Clinical presentation
A 54-year-old female patient visited the outpatient clinic in our institute in November 2017 due to an incidentally found mass in the head of the pancreas during a routine medical check-up. She had a generally goodlooking appearance and did not describe any symptoms.
Her body weight was 48.0 kg, and body mass index was 
Preoperative evaluation
Routine blood laboratory examinations, including serum amylase and lipase, were within the normal ranges.
The level of carbohydrate antigen 19-9 and carcinoembryonic antigen were 24.1 U/ml and 1.77 ng/ml, respectively. A contrast enhanced abdominal computed tomography (CT) scan revealed an approximately 2.7 cmsized low-attenuating mass in the head of the pancreas, without pancreatic duct dilatation (Fig. 1A) , and peripheral enhancement on the portal venous phase (Fig. 1B) .
Gallium (Ga)-68 DOTA-TOC and FDG PET/CT were performed for further evaluation, and there was no discernible Ga-68 DOTATOC and FDG uptake in the pan-
Operative finding
Considering the potential long-term survival of a patient with a preoperative diagnosis of a pancreatic solid pseudopapillary tumor or a neuroendocrine tumor, we performed a robot-assisted pylorus-preserving PD (laparoscopic resection followed by robotic reconstruction; pancreatojejunostomy and hepaticojejunostomy). The duodenojejunostomy was performed through a small, extended, periumbilical wound from which the surgical specimens were removed. It was noted that the remnant pancreas was soft, the pancreatic duct was 1 mm, and the resected bile duct size was 8 mm in diameter. The operation time was 300 minutes. Estimated blood loss was 200 ml, and no intraoperative transfusion was noted.
Pathological examination
Macroscopically, the cut surface of the pancreas showed an ill-defined, whitish, firm mass. On multiple serial sections, the cut surface showed a well-defined, whitish, lobular, firm mass (2.2×1.7 cm, Fig. 2A ). Microscopically, well-defined pancreatic acini and ductal elements were noted (Fig. 2B) . The immunohistochemical stain revealed negative results for CD34 and C-kit in the tumor cells (Fig. 2C, D) . Thus, the mass was confirmed as a pancreatic hamartoma
Postoperative course and follow-up 
DISCUSSION
Literature review
Twenty-five patients with pancreatic hamartoma have been reported [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] , including the present case. Excluding four pediatric patients, 18 21 adult patients with pancreatic hamartoma are summarized in Table 1 .
The patients were composed of nine males and 12 females, and the average age was 52.6±14.4 years, although there is one reported case in a newborn. Nine patients The location of the mass and the patient's nonspecific In recent studies, the safety and efficacy of minimally invasive pancreaticoduodenectomy (MI-PD) has been well documented, and it may be an effective treatment for wellselected benign and low-grade malignant tumors. 20 The development of a systematic surgical education program and management of its quality are important for the establishment of safe MI-PD surgeries.
